

I r r f r fH O r A M Dr
A r Pr r P N r ,N r

Fr O. r , Jr.,¹A E ,²J ~~_____~~² A ~~_____~~²J K ³
J D ,⁴H r M f ,⁵ ,⁶Gr r . N ,¹C , A ,⁶M I ⁶L r ,¹
E Gr ,^{1*} ~~_____~~⁷B. L. B. N , E Mr²

¹The Car er Cen er, A ia a, Ge ;g a; ²The Car er Cen er Nge a, J , Nge a; ³Pia ea S ae M r f Heal h, J , Nge a; ⁴Na a a S ae M r f f Heal h, Lafia, Nge a; ⁵Un er f J , J , Nge a; ⁶De ar en fP bic Heal h, Federai M r f f Heal h, Ab a, Nge a; ⁷Un er fS hFi da, Ta a, Fi da; ⁸

f ≥ 80%. 1991, 10 f r 23 LGA
 P f MDA. Af r N r fr
 P , LGA r fr fi -
 fi r fi - r f 12
 LGA fi r r ,
 f MDA (1). E LGA r r
 - r 5% f r
 (- r - , r rr fr “ -/
 ”) r .
 N r f “r r
 ” (EMO) , r -
 fi (-
) r , r G . 1998.¹⁰
 l r - MDA () 12 -
 r r (“ -/ r ”) -
 r LGA 1992–1993.^{7,9} r r ,
 r 80% f -
 - r M f H /NGO
 ff. C - r r 2–
 4 r r r r r
 r r M f H . r

r r r fi M f
 H /NGO ff. B 1994, r r
 f r r r MDA. l 1995, r r
 >80% r r . l 1996, MDA
 f r r “ - r
 r r ” r Afr Pr r
 f r O r C (APOC) ≥ 80% r r
 r r r . B f 2017, 12
 -/ r LGA r 25 26
 r f MDA (1). O r r r fr
 r -/ r LGA r r
 F r 2 (r r).

Lymphatic filariasis MDA in Plateau and Nasarawa states.

r fi r (LF) r r
 P N r
 .^{11–15} Br fl, 1997 f r r -
 f r LF . A 30 LGA r
 f r r 1% r r
 (F r 1), LGA r r fr 4%
 62%.¹²

LGA,¹¹ 30 LGA 2003 (February 2, 2003). Overall, 80% of the 30 LGAs had a prevalence of LF > 80% in 2003, with a median prevalence of 12% (range 0–100%). The prevalence of LF in 2003 was significantly higher than in 2002 (72.2% (95% CI 65.5–79.0)).¹² The prevalence of LF in 2003 was significantly higher than in 2002 (72.2% (95% CI 65.5–79.0)).¹² The prevalence of LF in 2003 was significantly higher than in 2002 (72.2% (95% CI 65.5–79.0)).¹²

LF MDA (18–21 months) was implemented in 18 LGAs in 2009. The prevalence of LF in 2009 was significantly lower than in 2003 (12% (95% CI 8–11%) vs 12% (95% CI 8–11%)). MDA was implemented in 12 LGAs in 2009. The prevalence of LF in 2009 was significantly lower than in 2003 (12% (95% CI 8–11%) vs 12% (95% CI 8–11%)). MDA was implemented in 12 LGAs in 2009. The prevalence of LF in 2009 was significantly lower than in 2003 (12% (95% CI 8–11%) vs 12% (95% CI 8–11%)).

Impact assessments for onchocerciasis during the MDA treatment interval. A total of 18 LGAs were included in the impact assessments. The prevalence of LF in 2009 was significantly lower than in 2003 (12% (95% CI 8–11%) vs 12% (95% CI 8–11%)). MDA was implemented in 12 LGAs in 2009. The prevalence of LF in 2009 was significantly lower than in 2003 (12% (95% CI 8–11%) vs 12% (95% CI 8–11%)).

“.../... LGA... 99% (38% vs 0.3%).”

HO f r MDA: 1) I G4 3,000 r
 O 16 r < 0.1% (r 95%

6,000 fl

r f LF MDA ffi “ - ”
 r (fi f r
 f1% <5%).N f2,063 r O 16 ,
 ffi r r f
 0.1% HO -MDA r .
 H r, 2018 (G. N , r
 , 2019) P LGA fM
 K r LGA) , f
 1,561 (6 7- r-) r r O 16 O 16-
 123 B r (r D ,
 , f K r).²⁷ lf r
 r fr -/ - , r

3,624 r ffi -
 0.1% (0% O 16 r ,
 OEPA O 16 ELI A r f r
 r (B O 16 r r , r
 D) r f r 1,000
 DB fr r f - r-
 LGA r N r . l , f
 99.3% r 99.7% r , 91.9% r
 r , r , 2019).
 r , r 13 -/ -
 r , r r ffi

fi (1,985) <1/2,000 f
fi r .
- LGA P r 5 r -/
(LF) MDA. r r -
f r r r r)
r f r , LF r r -
MDA r LF r r
r “ - ” r
(f r f 1% < 5%) r
r APOC “ - ”
fi r . I APOC/EMO ,
- r f r r 5
< 20%, r rr f r
r 35%.^{28,29} A r
r -/ - -
r LGA r r fi .

28. K -H LA, [redacted], MC, M DH, 2015. H - r : fi r f r r - r . *Infec D P er* 4: 36.

29. C ff LE ., 2013. Afr Pr r f r O r C r 1995-2015: - PL S Negi T; D : 2032.

30. AH, E E, I , A [redacted], M, C , A A, JH, 2012. I f r N r : fir r Afr Pr r f r O r C r . *Para Vec* 5: 28.

31. B D ., 2018. f r Afr : r r r r r . *In Heal h* 10: 27-32.

32. Pr r C r C OEPA ff, 2012. G Re Re T; Med 3: 21-33.

33. M, P r AP, A E , N r NJ, O r G, B BA, H JD, 2002. C r Afr ? *B il W id Heal h Organ* 80: 384-391.

34. D r L ., 2009. F f r Afr : fir - fr M . *PL S Negi T; D* 3: 497.

35. A, r M, C ff LE, B MG, J, 2015. r r f Afr : r r r r r . *Para Vec* 8: 552.